checkAd

    Vivus heute erneut bei + 25 % - 500 Beiträge pro Seite

    eröffnet am 14.01.00 12:16:44 von
    neuester Beitrag 04.03.00 13:31:53 von
    Beiträge: 17
    ID: 50.847
    Aufrufe heute: 0
    Gesamt: 898
    Aktive User: 0

    ISIN: US9285513084 · WKN: A2N5RJ
    0,3200
     
    EUR
    -3,61 %
    -0,0120 EUR
    Letzter Kurs 20.07.20 Düsseldorf

    Werte aus der Branche Biotechnologie

    WertpapierKursPerf. %
    3,1100+804,86
    1,4550+127,70
    2,8300+73,62
    0,5299+52,04
    12,390+32,23
    WertpapierKursPerf. %
    1,8000-19,64
    0,7603-23,97
    5,3700-27,92
    2,0400-35,44
    3,5100-46,00

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 14.01.00 12:16:44
      Beitrag Nr. 1 ()
      Hallo Ihr,

      beobachten mal Vivus, die Aktie war vor 2,5 Jahren bei 50 Eu und ist dann bis auf 2 EU abgesunken (wegen Medikamente die keine Zulassung erhalten haben.) Vor 3 Wochen ist die Aktie innerhalb von 2 Tagen von 2 EU auf 5 EU gestiegen.

      Nach Gewinnmitnahmen ist sie wieder bis 3 Eu gefallen. Nun notiert Sie wieder bei 4,70 EU.

      Da erneut Krebs Medikamente vor der Zulassung stehen, denke ich das wir in geraumer Zeit evt. alte Höchstkurse sehen könnten.

      Übrigens in Amerika 4 X Strong Buy


      So long
      Sidney
      Avatar
      schrieb am 15.01.00 11:57:37
      Beitrag Nr. 2 ()
      bin sehr interesiert an dieser aktie.
      wie hoch sieht ihr die kurschancen.
      kann mir jemand etwas genaueres über diese aktie sagen.

      dank thunder
      Avatar
      schrieb am 16.01.00 17:10:11
      Beitrag Nr. 3 ()
      wo finde ich was zu den krebsmitteln - finde immer nur Viagra ersatz

      was haben die noch so alles ?
      Avatar
      schrieb am 20.01.00 14:36:39
      Beitrag Nr. 4 ()
      Hallo,

      mich wundert ja, das noch keiner was gepostet hat und die News schon seit Stunden draußen sind.

      Esp/share waren je nach Quelle -0,05 bis zu +0,04 und Flüsterschätzung von 0,08 USD bei www.earningswhispers.com.

      Rauskommen werden aber wahrscheinlich 0,4-0,42 USd für das 4.Q.

      893380 ist die WKN in D., z.Z. 6,3€ =35% Aufschlag, allerdings erste bidkurse bei 6,5-7.

      ----------
      VIVUS Announces Higher Than Expected Fourth Quarter Earnings Per Share; Company Expects To Report Between $0.40 and $0.42 EPS

      BusinessWire
      Thursday January 20 4:03am

      MOUNTAIN VIEW, Calif.--(BW HealthWire)--Jan. 20, 2000--VIVUS, Inc. (Nasdaq:VVUS) today announced that the Company expects to report earnings per share ("EPS") between $0.40 and $0.42 for its fourth quarter of 1999. The increase in EPS is primarily due to additional revenues recorded as part of the resolution of financial obligations related to the return to VIVUS of marketing and distribution rights for MUSE(R) (alprostadil) from AstraZeneca.

      Complete details of the Company`s quarterly and year end financial results will be available in a press release to be issued on January 26, 2000 at the close of market. VIVUS invites shareholders and the financial community to participate in its conference call which will be held at 4:30 p.m. Eastern Time on January 26, 2000. The call can be accessed via a live webcast on the Internet at www.vcall.com or www.streetfusion.com.

      VIVUS, Inc. is the developer and manufacturer of MUSE and ACTIS(R), two innovations in the treatment of men with erectile dysfunction ("ED"), also known as impotence. The Company`s objective is to become a global leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. VIVUS has ongoing research and development programs in female sexual dysfunction and male premature ejaculation. The company recently filed a New Drug Application with the FDA for ALIBRA(R), its second-generation male ED treatment.

      Note to Editors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).

      Contact: VIVUS, Inc.
      Barbara Clark, 650/934-5200
      Manager, Investor Relations
      ir@vivus.com


      Source: BusinessWire



      VIVUS Announces Higher Than Expected Fourth Quarter Earnings Per Share; Company Expects To Report Between $0.40 and $0.42 EPS

      BusinessWire
      Thursday January 20 4:03am

      MOUNTAIN VIEW, Calif.--(BW HealthWire)--Jan. 20, 2000--VIVUS, Inc. (Nasdaq:VVUS) today announced that the Company expects to report earnings per share ("EPS") between $0.40 and $0.42 for its fourth quarter of 1999. The increase in EPS is primarily due to additional revenues recorded as part of the resolution of financial obligations related to the return to VIVUS of marketing and distribution rights for MUSE(R) (alprostadil) from AstraZeneca.

      Complete details of the Company`s quarterly and year end financial results will be available in a press release to be issued on January 26, 2000 at the close of market. VIVUS invites shareholders and the financial community to participate in its conference call which will be held at 4:30 p.m. Eastern Time on January 26, 2000. The call can be accessed via a live webcast on the Internet at www.vcall.com or www.streetfusion.com.

      VIVUS, Inc. is the developer and manufacturer of MUSE and ACTIS(R), two innovations in the treatment of men with erectile dysfunction ("ED"), also known as impotence. The Company`s objective is to become a global leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. VIVUS has ongoing research and development programs in female sexual dysfunction and male premature ejaculation. The company recently filed a New Drug Application with the FDA for ALIBRA(R), its second-generation male ED treatment.

      Note to Editors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).

      Contact: VIVUS, Inc.
      Barbara Clark, 650/934-5200
      Manager, Investor Relations
      ir@vivus.com


      Source: BusinessWire

      iel Spaß
      Avatar
      schrieb am 20.01.00 14:37:38
      Beitrag Nr. 5 ()
      Sorry, doppelt

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 20.01.00 15:19:25
      Beitrag Nr. 6 ()
      Hallo Magoo,

      mein Englisch ist nicht so toll, kannst Du mal in kurzen Worte den Text ins deutsche übersetzen !!
      Danke im voraus.

      Übrigens VIVUS aktuell 7,10 (+44 %)

      go VIVUS go $$$$$$$$$$$$$$$$$$
      Avatar
      schrieb am 20.01.00 23:05:34
      Beitrag Nr. 7 ()
      Nur eine klitze kleine Aufklärung über diese Aktie. Vivus Inc. beschäftigt sich zur Zeit mit Problemen der Impotenzen. Sie haben nichts mit Krebs zu tun soweit ich weiß. Das Produkt was sie ver-
      treiben ist genau wie Viagra aber glücklicherweise nicht so giftig. D. h. die Nevenwirkungen sind nicht so intensiv. Ich nehme an es gibt einer große Markt für dieses Medikament. Leider gibt es auch andere Firmen, die noch größer sind z. B. Takeda Chemical, die diesen Markt betreten wollen. Vivus hat potenzial, aber ist nur ein kleiner Fisch im Biotechsee. D.h. es könnte dazukommen, dass irgendwann Vivus aufgefressen wird oder sogar das erlaubt aufgefressen zu werden, weil ihr Produktpipeline nicht so aussichtsreich ist. Ich habe auch gehört, dass der Biotechsektor sich irgendwann konsolidieren wird. Ich habe es mir auch überlegt, ob ich die Aktie kaufen soll. Ich frage mich ob es noch Luft nach oben gibt. Die gekündigte Erlöse für das Quartal waren überraschend, aber dies ist der Fall momentan bei vielen Geschäften. Irgendwann ist der Spass vorbei!

      Dr. Dollar
      Avatar
      schrieb am 27.01.00 07:56:13
      Beitrag Nr. 8 ()
      Hallo,

      um es also kurz zu machen, VVUS hat die eigenen Schätzungen sogar nochmals überboten.

      0,43 USD, ausschlaggebend sicherlich der Deal mit Astra Zeneca und den Vertiebssrechten von Alprostadil.

      Die Nachricht kam nachbörslich, also achtet darauf wie die Amis reagieren.

      Viel Spaß u. hier die News

      -----------------------------

      VIVUS Reports 1999 Year End and Fourth Quarter Financial Results; VIVUS Earns $0.43 Per Share for the Quarter and $0.58 for the Year

      BusinessWire
      Wednesday January 26 4:03pm

      MOUNTAIN VIEW, Calif.--(BW HealthWire)--Jan. 26, 2000--VIVUS, Inc. (Nasdaq:VVUS) today reported net income of $13.8 million, or $0.43 per diluted share, on $21.5 million in total revenue for the fourth quarter, and net income of $18.8 million, or $0.58 per diluted share, on $43.2 million in total revenue for the year ended December 31, 1999. These results compare to net income of $1.0 million, or $0.03 per diluted share, on $11.1 million in total revenue for the fourth quarter of 1998, and a loss of $80.3 million, or $2.52 loss per share, on $74.7 million in total revenue for the year ended December 31, 1998.

      Cash, cash equivalents and available-for-sale securities at December 31, 1999 totaled $40.4 million, compared to $23.9 million at December 31, 1998, an increase of $16.5 million. Total liabilities at December 31, 1999 were $27.3 million, compared to $32.4 million at December 31, 1998, a decrease of $5.1 million.

      U.S. product revenue for the fourth quarter of 1999 was $5.8 million, compared to $4.9 million in the fourth quarter of 1998, an increase of 18 percent. International product revenue for the fourth quarter of 1999 was $15.6 million, compared to $6.3 million in the fourth quarter of 1998, an increase of $9.3 million.

      During the fourth quarter of 1999, the Company reached agreement with AstraZeneca regarding the financial obligations related to the return of marketing and distribution rights for MUSE(R) (alprostadil). As a result of this resolution, the Company recorded $20 million in revenue during the quarter, consisting of $14.9 million in product revenue associated with shipments that occurred throughout 1998 and 1999, $2 million in milestone revenue associated with marketing clearance in Italy, and $3.1 million in other revenue.

      Product revenue for the year ended December 31, 1999 was $41.2 million, compared to $71.7 million in the same period of 1998, a decrease of $30.5 million. Lower U.S. product revenue is due primarily to the commercial launch of a competitive treatment for erectile dysfunction in April 1998. Lower international revenue is primarily due to lower shipments during 1999 as the Company`s international distributors had sufficient inventory to support these markets.

      The fourth quarter and year ended December 31, 1999 include a $5.0 million and $9.1 million charge, respectively, for the return of expired product in the U.S. These returns are primarily the result of shipments made prior to the decline in demand for MUSE following the launch of a competitive product in April 1998.

      Operating expenses were 28 percent lower for the fourth quarter and 84 percent lower for the year ended December 31, 1999 compared to the same periods in 1998. The decrease in expenses is primarily due to the Company`s efforts during 1999 to bring the cost structure of the business in line with its current and projected revenues.

      VIVUS, Inc. is the developer and manufacturer of MUSE and ACTIS(R), two innovations in the treatment of men with erectile dysfunction, also known as impotence. The Company`s objective is to become a global leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. VIVUS has ongoing research and development programs in female sexual dysfunction and male premature ejaculation. The company recently filed a New Drug Application with the FDA for ALIBRA(R), its second-generation male ED treatment.

      Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).

      -0- *T

      Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).

      VIVUS, Inc.
      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
      (in thousands, except per share amounts)

      Three Months Ended Twelve Months Ended
      -------------------------------------------------
      December 31, December 31, December 31, December 31,
      1999 1998 1999 1998
      -------------------------------------------------
      (unaudited) (unaudited)
      Revenue
      US product $ 5,751 $ 4,863 $ 21,168 $ 39,041
      International
      product 15,603 6,267 19,996 32,658
      Milestone 2,000 -- 8,000 3,000
      Other revenue 3,142 -- 3,142 --
      Returns (5,000) -- (9,118) --
      --------- --------- --------- ---------
      Total revenue 21,496 11,130 43,188 74,699

      Operating Expenses
      Cost of goods sold 2,854 6,133 12,369 55,616
      Research and
      development 2,920 2,266 7,884 16,178
      Selling, general
      and administrative 1,707 1,961 6,332 40,477
      Settlement of
      shareholder lawsuits -- -- 600 --
      Write-down of
      property -- -- -- 32,163
      Other restructuring
      costs -- -- (1,793) 12,490
      --------- --------- --------- ---------

      Total operating
      expenses 7,481 10,360 25,392 156,924
      --------- --------- --------- ---------

      Income (loss)
      from operations 14,015 770 17,796 (82,225)

      Interest and
      other income 532 270 1,994 1,972
      --------- --------- --------- ---------

      Income (loss)
      before taxes 14,547 1,040 19,790 (80,253)

      Income tax
      provision (727) -- (989) --
      --------- --------- --------- ---------

      Net income
      (loss) $ 13,820 $ 1,040 $ 18,801 $ (80,253)
      ========= ========= ========= =========


      Net income (loss)
      per share:
      Basic $ 0.43 $ 0.03 $ 0.59 $ (2.52)

      Diluted $ 0.43 $ 0.03 $ 0.58 $ (2.52)

      Shares used
      in the
      computation of
      net income (loss)
      per share:
      Basic 32,193 31,869 32,085 31,876

      Diluted 32,402 32,115 32,507 31,876


      VIVUS, Inc.
      CONDENSED CONSOLIDATED BALANCE SHEETS
      (in thousands)


      December 31, December 31,
      1999 1998

      Current assets:
      Cash $ 8,785 $ 2,989
      Available-for-sale securities 27,049 20,903
      Accounts receivable 2,074 5,197
      Inventories 3,527 5,272
      Prepaid expenses and other assets 6,696 534
      --------- ---------
      Total current assets 48,131 34,895

      Property and equipment 16,071 19,213
      Available-for-sale
      securities, non-current 4,558 --
      --------- ---------
      Total $ 68,760 $ 54,108
      ========= =========

      Current Liabilities:
      Accounts payable $ 2,453 $ 3,277
      Accrued and other liabilities 19,062 21,294
      --------- ---------
      Total current liabilities 21,515 24,571
      Accrued and other long-term liabilities 5,749 7,860
      --------- ---------
      Total liabilities 27,264 32,431

      Stockholders` equity:
      Common stock; $.001
      par value; shares
      authorized 200,000;
      shares outstanding -
      December 31, 1999 32,211;
      December 31, 1998, 31,890 32 32

      Paid in capital 132,643 131,466
      Accumulated other comprehensive income (190) (31)
      Accumulated deficit (90,989) (109,790)
      --------- ---------
      Total stockholders` equity 41,496 21,677
      --------- ---------
      Total $ 68,760 $ 54,108
      ========= =========

      *T

      Contact: VIVUS, Inc.
      Barbara Clark, 650/934-5200 (Investor Relations)
      ir@vivus.com
      Avatar
      schrieb am 27.01.00 15:48:37
      Beitrag Nr. 9 ()
      Hallo
      Vivus heute auf Grund der super Q-Zahlen erneut 20 % im Plus aktuell 6,90 Eu. Ich bin vor 5 Wochen bei 3,20 eingestiegen.

      Gruß Sidney
      Avatar
      schrieb am 05.02.00 22:06:44
      Beitrag Nr. 10 ()
      Hi Sidney, sag mal wo kann man die "Strong buy" - Ratings
      nachlesen? Ich habe sie in Yahoo Finance/Profile nicht gefunden.
      Die letzte Stong buy steht hier unter 1998.

      Grüße
      Avatar
      schrieb am 03.03.00 11:52:28
      Beitrag Nr. 11 ()
      Hallo Ihr Börsianer,

      die wo meinen Beitrag gelesen haben, können sich bestimmt noch an meine Kaufempfehlung im Dezember erinnern. Momentan ist Vivus erneut 25 % im Plus bei 7,50 Eu (Dezember 99 4,50 EU)

      Und das schöne ist es geht erst richtig los.


      $$$$$$$$$
      mfg

      so long
      Avatar
      schrieb am 03.03.00 15:33:48
      Beitrag Nr. 12 ()
      8 EU aktuell

      $$$$$
      Avatar
      schrieb am 03.03.00 16:40:24
      Beitrag Nr. 13 ()
      sagt mal Kenner,


      wie begründet sich der Anstieg von Vivus?

      ist das neue Medikament (alibra o.ä.) draußen? Sind Zahlen unterwegs?

      Danke

      Juttol
      Avatar
      schrieb am 03.03.00 16:40:25
      Beitrag Nr. 14 ()
      sagt mal Kenner,


      wie begründet sich der Anstieg von Vivus?

      ist das neue Medikament (alibra o.ä.) draußen? Sind Zahlen unterwegs?

      Danke

      Juttol
      Avatar
      schrieb am 03.03.00 22:28:57
      Beitrag Nr. 15 ()
      Horridau allerseits,


      Stock of the Hour Mar 3 2000 10:30AM CST Archives...


      Vivus Barrels Higher on Enormous Strength
      by Blair G. Jeffery

      Shares of Vivus, Incorporated {VVUS} appeared in the 11:20 a.m. ProSearch run of Stocks Breaking Out To New 52-Week Highs after the stock gained 3/4 of a point to $8-1/4 on a 100 percent increase in average trading volume.

      The chart below shows an impressive run higher for Vivus since its low in mid-December. The stock has gained more than 325 percent in the last twelve weeks of trading, culminating with today`s breakout to a new record high on very strong trading volume.


      VVUS` 12-month chart with Wilder RSI Indicator, 30-day moving average

      Vivus develops other treatments for erectile dysfunction. The company`s first product, MUSE, is a small, single-use disposable plastic applicator that dispenses the drug alprostadil to increase blood flow in the penis. Its other marketed product is ACTIS, a fully adjustable penile band that temporarily helps correct venous leak (a cause of erectile dysfunction). VIVUS is also developing treatments for female sexual dysfunction, urinary incontinence, and other urologic disorders. To help regain market share lost to Viagra, the company contracted with a Johnson & Johnson subsidiary to market MUSE overseas.

      Technically speaking, shares of Vivus appear slightly overbought in the short-term, trading with a Wilder RSI reading of 77, more than 7 points higher than the 70 overbought line. The Wilder tracks a stock`s movements based on higher highs and lower lows and gives a smoothed reading of the stock`s valuation position. When the stock moves higher than a 70 on the Wilder reading, a caution flag should be raised. This overbought position does not mean the stock will decline, but means the stock may be ahead of itself at this level. Basically, tread lightly on these shares.

      The stock is also trading significantly higher than its 50 and 200-day moving average lines with a 177 and 251 percent divergence, respectively. These indicators also may point to an overbought position in the stock. Look for the stock to dip to support in the 6-1/2 or 7 range for indication of a renewed upward trend.

      LONG WITH VIVUS

      Gruss SMC1
      Avatar
      schrieb am 04.03.00 13:01:31
      Beitrag Nr. 16 ()
      Horridau allerseits,

      Small Business


      --------------------------------------------------------------------------------


      I will survive
      Overtaken by a competitor, Vivus quickly shifted gears
      Peter Delevett Business Journal Staff Writer
      Betamax. Atari. The five-inch floppy disk.

      Once upon a time, these technologies were as hot as Silicon Valley real estate. Now, they`re right up there with the Bay City Rollers.

      So what does a company do when its product is made obsolete by a competitor?

      Focus on survival, says Leland Wilson.

      The CEO and president of Mountain View medical technology company Vivus Inc., Mr. Wilson was riding high in 1997 with the debut of his company`s drug, Muse.

      The drug was the top-selling treatment for male impotence that year, with sales of $129 million.

      Then, in April 1998, a word appeared that became embedded overnight in the American vocabulary: Viagra.

      Last dance?
      "There has never been a launch comparable in the history of pharmaceuticals," Mr. Wilson says of Pfizer Inc.`s impotence pill.

      Viagra set records with $182 million in sales in its first two months on the market. A muscular direct-to-consumer advertising campaign had patients clamoring for the drug; at one point, Mr. Wilson says, doctors were writing more than 300,000 new prescriptions for Viagra every week.

      Demand for Muse dropped like a stone. In second quarter 1998, Vivus recorded a net loss of $22 million--compared to net income of $10 million a year earlier.

      "People were betting we were going out of business," Mr. Wilson remembers.

      Vivus stock, trading at $40 a share in fall 1997, had plunged to $2.50 a year later.

      Many doomsayers believed the end was near when, in August 1998, Vivus retained investment banking firm Credit Suisse First Boston Corp. to help "evaluate strategic alternatives," including possible sale of the company.

      It wasn`t just advertising dollars that made consumers go ga-ga for Viagra. The fact that the drug comes in a pill made it easier for patients to swallow--literally.

      Muse, by contrast, is a gel that`s delivered into the tip of the penis via a tube. Not exactly a boost to the romantic mood.

      Looks like we made it
      Fast forward to today: Vivus recently completed its fifth consecutive profitable quarter.

      Net income for 1999 was $18 million--half that of 1997, but not shabby. And per-share earnings in the latest quarter beat analysts` estimates.

      How did Vivus return from the edge of extinction to profitability?

      "Clearly we had to develop a brand-new business model, and we had to react very, very fast," Mr. Wilson says.

      He engineered a complete reorganization of the company, along with dramatic layoffs.

      Vivus has never before made public just how many workers were let go, but Mr. Wilson says when the cutting was done, the firm was down to around 120 employees from a high of 600.

      Included in that was the company`s entire staff of 75 sales reps.

      In addition, Vivus leased out its Mountain View headquarters and consolidated its remaining staff into a portion of the building. Mr. Wilson renegotiated contracts with suppliers and dropped an expensive contract manufacturing partnership.

      "We became very careful with every dollar we had," he says.

      But he didn`t skimp on anything related to the development of new products, recognizing the company`s R&D pipeline represented its future.

      The first payoff came last December, when Vivus filed a New Drug Application with the Food and Drug Administration for Alibra, a second-generation drug that Mr. Wilson says is more effective than Muse and has fewer side effects.

      He expects FDA approval next January and is already gearing up for a product launch.

      Stayin` alive
      Not every step Mr. Wilson took in response to Viagra worked. He admits now he wasted millions of dollars at first trying to fight Pfizer`s juggernaut.

      "With [Pfizer`s] direct access marketing to patients, our sales representatives were basically neutered out there," he says. "The doctors weren`t in the decision-making process."

      After realizing its sales reps couldn`t turn things around and cutting them loose, Vivus began looking to partner with a bigger pharmaceutical company who could sell Muse.

      But a worldwide marketing deal with European drug firm AstraZeneca didn`t work out. After Astra AB of Sweden, which had agreed to distribute Muse, merged in April with London-based Zeneca Group plc, Muse no longer was a high priority for the merged company`s management. As a result, Muse still hasn`t been launched in a number of countries where it`s been approved for sale.

      Vivus now is looking for another partner to promote the drug abroad. Here at home, the company has slowly begun rebuilding its sales force, targeting its marketing efforts on just a few thousand urologists nationwide.

      Selling a drug with only about 15 sales reps runs counter to conventional wisdom that you need a big sales force to succeed. "A lot of people say that; obviously they`re wrong," Mr. Wilson says. "It`s been very cost-effective for us."

      Still, the tactic only allows Vivus to nibble around the edges of Viagra`s market, which targets general practitioners, a much larger audience. Mr. Wilson is betting Alibra will be better able to compete for those doctors--and he realizes Vivus will need a big partner to make that strategy fly.

      Alibra, like Muse, will have to be administered into the penis; Vivus has experimented with an oral application but hasn`t succeeded. The company has tried to pitch that as a strength, arguing that its delivery method produces fewer side effects than Viagra because the drug isn`t carried throughout the circulatory system.

      Ultimately, Vivus aims to capitalize on patients for whom Viagra doesn`t work or isn`t safe to use, such as men with heart conditions or diabetes. After the initial craze, Viagra lost some of its luster when several dozen patients died after taking it.

      Mr. Wilson says Viagra prescriptions have dropped to about half of 1998 levels, though the drug still boasts $900 million in annual sales.

      "We knew there was tremendous euphoria about Viagra when the pill was launched, and we knew the product was not going to meet expectations," Mr. Wilson says. "They have a very high dropout rate."

      The key for Vivus, he says, has been waiting out the storm.

      Despite the company`s turnaround, Vivus` stock price remains mired in the $5 range. Mr. Wilson knows investors won`t come back to the fold unless Alibra proves successful.

      "I`ve learned more in the past two years than I did in the previous 20," he says.

      You can reach Mr. Delevett at pdelevett@amcity.com.


      LONG WITH VIVUS


      GRUSS SMC1
      Avatar
      schrieb am 04.03.00 13:31:53
      Beitrag Nr. 17 ()
      Horridau allerseits,

      nächste Woche sehen wir die 12-14 $.

      Stock Analysis of Vivus Inc.


      Thank you for requesting an analysis of Vivus Inc. from VectorVest ProGraphics. The ticker symbol for Vivus Inc. is VVUS. VVUS is traded on the NASDAQ and options are available on this stock.

      PRICE: VVUS closed on 03/03/2000 at $8.00 per share.

      VALUE: VVUS has a Value of $8 per share. Value is the foundation of the VectorVest system. It is a measure of what a stock is currently worth. Value is based upon earnings, earnings growth rate, dividend payments, dividend growth rate, and financial performance. Current interest and inflation rates also play an important role in the computation of Value. When interest and/or inflation rates decrease, Value goes up. When interest rates and inflation increase, Value goes down. Sooner or later a stock`s Price and Value always converge.

      RV (Relative Value): VVUS has an RV of 1.01. On a scale of 0.00 to 2.00, an RV of 1.01 is fair. RV reflects the long-term price appreciation potential of the stock compared to an alternative investment in AAA Corporate Bonds. Stocks with RV ratings above 1.00 have attractive upside potential. A stock will have an RV greater than 1.00 when its Value is greater than Price, and its Relative Safety (see below) and forecasted earnings growth rate are above average. In some cases, however, a stock`s RV will be above 1.00 even though its Value is well below Price. This happens when a stock has an exemplary record of financial performance and an above average earnings growth rate. In this case, the stock is currently selling at a premium, and the investor is banking on future earnings growth to drive the stock`s price higher. This information is very useful not only in knowing whether or not a stock has favorable price appreciation potential, but it also solves the riddle of whether to buy high growth, high P/E, or low growth, low P/E stocks.

      We believe that RV ratings above 1.00 are required to consistently achieve above average capital gains in the stock market.

      RS (Relative Safety): VVUS has an RS rating of 0.64. On a scale of 0.00 to 2.00, an RS of 0.64 is poor. VectorVest looks at safety from the viewpoint of an equity investor (one who is buying stock of a company) rather than that of a purchaser of debt (one who is lending money to the company). From this perspective, consistency of financial and operating performance, stock price appreciation history, and price volatility are the key factors used in the evaluation of Relative Safety (RS). Debt to equity ratio, capitalization, sales volume, business longevity and other factors are also considered, but to a lesser degree.

      VectorVest favors steady, predictable performers. All stocks are rated on a scale of 0.00 to 2.00. A stock with an RS greater than 1.00 is safer and more predictable than the average of all stocks. A stock with an RS less than 1.00 is less predictable and riskier than the average stock.

      RT (Relative Timing): VVUS has an RT rating of 2. On a scale of 0.00 to 2.00, an RT of 2 is excellent. RT is a fast, responsive, short-term price trend indicator. It analyzes the direction, magnitude, and dynamics of a stock`s price behavior over the last 13 weeks; then reflects and projects the short-term price performance of the stock. Once a stock`s Price has established a strong trend, it is expected to continue that trend for the short-term. If the trend dissipates, RT will gravitate towards 1.00. Should the price change dramatically, RT will notice the crucial turning point. When warranted, it will explode from a Price low and dive from a Price high.

      All stocks are rated on a scale of 0.00 to 2.00. If RT is above 1.00,the stock`s Price is in an uptrend. Below 1.00, the stock`s Price is in a downtrend.

      VST-Vector (VST): VVUS has a VST-Vector rating of 1.39. On a scale of 0.00 to 2.00, an VST of 1.39 is excellent. VST-Vector solves the dilemma of balancing Value, Safety and Timing. Stocks with high RV values often have low RS values, or stocks withlow RV and RS values have high RT`s. How can we find the stocks with the best combinations of Value, Safety, and Timing?

      The classic vector formula (square root of the sum of the squares) handles this problem. It combines a set of forces into a single indicator for ranking every stock in the VectorVest database. Stocks with the highest VST-Vector have the best combinations of Value, Safety and Timing. These are the ones to own for above average capital application.

      GRT (Growth Rate): VVUS has a GRT of 26 % per year. This is excellent. GRT stands for forecasted Earnings Growth Rate in percent per year. GRT is updated each week for every stock. Watch GRT trends very carefully. If the GRT trend is up, the stock`s Price will likely rise. If the GRT trend is down, the stock`s Price will increase more slowly, cease to increase, or subsequently fall.

      Recommendation (REC): VVUS has a Buy recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks which are rising in price, and to avoid or sell risky, overvalued stocks which are falling in price.

      VectorVest is tuned to give an "H" or "B" signal when a stock`s price is approximately 10% above a recent low, and an "S" signal when the stock`s price is approximately 10% below a recent high. High RV, RS stocks are favored toward receiving "B" REC`s, and sheltered from receiving "S" RECs.

      STOP-PRICE: VVUS has a Stop-Price of 4.30 per share. This is 3.70 or 46.3% belowits current closing Price. VectorVest analyzes over 6,000 stocks each day for Value, Safety and Timing, and calculates a Stop-Price for each stock. These Stop-Prices are based upon 13 week moving averages of closing prices, and are fine-tuned according to each stock`s fundamentals.

      In the VectorVest system, a stock gets a "B" or an "H" recommendation if its price is above its Stop-Price, and an "S" recommendation if its price is below its Stop-Price.

      DIV (Dividend): VVUS does not pay a dividend. VectorVest focuses on annual, regular, cash dividends indicated by the most recent disbursement. Special distributions, one-time payments, stock dividends, etc., generally are not included in Dividend (DIV).

      DY (Dividend Yield): VVUS has a DY of 0 percent. This is above the current market average of percent. DY equals 100 x (DIV/PRICE), and is expressed as a percentage.

      EY (Earnings Yield): VVUS has an EY of 6.43%. This is above the current market average of %. EY equals 100 x (EARNINGS PER SHARE/PRICE), and is expressed as a percentage.

      EPS (Earnings Per Share): VVUS has an EPS of $0.51 per share. EPS stands for leading 12 months Earnings Per Share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.

      P/E (Price to Earnings Ratio): VVUS has a P/E ratio of 15.69. This ratio is computed daily based upon Price and EPS. P/E = Price/EPS.

      GPE (Growth to P/E Ratio): VVUS has a GPE of 1.67. This ratio suggests that This ratio suggests that VVUSis undervalued. Growth to P/E ratio is a popular measure of stock valuation which compares Earnings Growth Rate (GRT) to Price Earnings ratio (P/E). A stock is considered to be undervalued when GPE is greater than 1.00, and vice-versa. VectorVest believes that RV is a much better indicator of long-term value. The RV of 1.01 for VVUSis fair.

      DS (Dividend Safety): VVUS has a DS of 0. On a scale of 0 to 99, a DS of 0 is poor. DS is defined as the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. Stocks with DS values above 50 on a scale of 0 to 99 areabove average in safety.

      RISK (Dividend Risk): VVUS does not pay a dividend. All stocks in the VectorVest system that pay dividends are classified as having Low, Medium or High Dividend Risk (RISK). Stocks with DS values above 50 are above average in safety. These stocks are classified as having LOW or MEDIUM RISK. Stocks with DS values below 50 are below average in safety and are classified as having HIGH Risk.

      DG (Dividend Growth): VVUS has a DG of 0 percent per year. Dividend Growth is a subtle yet important indicator of a company`s historical financial performance and the board`s current outlook on the future use of funds.

      YSG-VECTOR (Yield-Safety-Growth Vector): VVUS has a YSG-Vector of 0. On a scale of 0.00 to 2.00, an YSG-Vector rating of 0 is very poor. VectorVest combines Dividend YIELD, SAFETY and GROWTH into a single parameter. YSG-Vector allows direct comparison of all dividend paying stocks. Stocks with the highest YSG-Vector values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.

      VOL(100)s: VVUS traded 4469500 shares on 03/03/2000.

      AVG VOL(100)s: VVUS has an Average Volume of 1842800. Average Volume is 50 day moving average of daily volume as computed by VectorVest.

      % VOL: VVUS had a Volume change of 142.5% from its 50 day moving average volume.

      OPEN: VVUS opened trading at $7.94 per share on 03/03/2000.

      HIGH: VVUS traded at a high of $8.63 per share on 03/03/2000.

      LOW: VVUS traded at a low of $7.63 per share on 03/03/2000.

      CLOSE: VVUS Closed trading at $8.00 per share on 03/03/2000.

      % PRC: VVUS showed a Price change of 6.7% from the prior day`s closing price.

      INDUSTRY: VVUShas been assigned to the Healthcare (Products) Group. VectorVest classifies stocks into over 190 Industry Groups and 50 Business Sectors.

      VVUS has well below average safety with about average upside potential. It reflects a stock which is likely to give about average, inconsistent returns over the long term.

      The basic strategy of VectorVest is to buy low risk, high reward stocks. We suggest that Prudent investors buy enough high Relative Value, high Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you`ll find that your risk will go down and your investment performance will improve. Not a bad combination.


      Gruss SMC1


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      -0,48
      -0,02
      +2,57
      +11,83
      -0,15
      +0,79
      -0,47
      +0,03
      +0,37
      +0,51
      Vivus heute erneut bei + 25 %